BNTC
Income statement / Annual
Last year (2026), Benitec Biopharma Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2026, Benitec Biopharma Inc's net income was -$45.55 M.
See Benitec Biopharma Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2026
|
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
06/30/2026 |
06/30/2025 |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$75.00 K |
$73.00 K |
$59.00 K |
$97.00 K |
$17.45 M |
$4.40 M |
$195.88 K |
| Cost of Revenue |
$481.00 K
|
$396.00 K
|
$343.00 K
|
$0.00
|
$9.00 K
|
$123.00 K
|
-$185.00 K
|
$622.17 K
|
$473.97 K
|
$160.00 K
|
| Gross Profit |
-$481.00 K
|
-$396.00 K
|
-$343.00 K
|
$75.00 K
|
$64.00 K
|
-$64.00 K
|
$282.00 K
|
$15.90 M
|
$3.95 M
|
$35.88 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
1
|
0.88
|
-1.08
|
2.91
|
0.91
|
0.9
|
0.18
|
| Research and Development Expenses |
$23.39 M
|
$18.33 M
|
$15.61 M
|
$12.77 M
|
$11.27 M
|
$7.02 M
|
$3.00 M
|
$3.19 M
|
$3.73 M
|
$4.07 M
|
| General & Administrative Expenses |
$27.80 M
|
$23.43 M
|
$6.99 M
|
$6.38 M
|
$6.65 M
|
$6.51 M
|
$5.57 M
|
$3.23 M
|
$4.72 M
|
$5.35 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$27.80 M
|
$23.43 M
|
$6.99 M
|
$6.38 M
|
$6.65 M
|
$6.51 M
|
$5.57 M
|
$3.23 M
|
$4.72 M
|
$5.35 M
|
| Other Expenses |
-$481.00 K
|
-$396.00 K
|
-$108.00 K
|
$0.00
|
$0.00
|
$0.00
|
-$5.00 K
|
$6.71 M
|
$8.18 M
|
$2.80 M
|
| Operating Expenses |
$50.71 M
|
$41.37 M
|
$22.49 M
|
$19.16 M
|
$17.92 M
|
$13.53 M
|
$8.56 M
|
$13.13 M
|
$16.63 M
|
$12.23 M
|
| Cost And Expenses |
$51.19 M
|
$41.77 M
|
$22.49 M
|
$19.16 M
|
$17.93 M
|
$13.66 M
|
$8.38 M
|
$13.75 M
|
$17.10 M
|
$12.39 M
|
| Interest Income |
$5.57 M
|
$0.00
|
$904.00 K
|
$0.00
|
$0.00
|
$0.00
|
$62.00 K
|
$85.28 K
|
$253.96 K
|
$249.13 K
|
| Interest Expense |
$0.00
|
-$3.29 M
|
$0.00
|
$33.00 K
|
$32.00 K
|
$6.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$481.00 K
|
$396.00 K
|
$343.00 K
|
$381.00 K
|
$392.00 K
|
$424.00 K
|
$374.00 K
|
$224.28 K
|
$194.96 K
|
$217.00 K
|
| EBITDA |
-$50.71 M |
-$41.37 M |
-$22.15 M |
-$18.70 M |
-$17.78 M |
-$13.45 M |
-$7.91 M |
$2.03 M |
-$16.51 M |
-$3.12 M |
| EBITDA Ratio |
0
|
0
|
0
|
-249.33
|
-243.62
|
-228
|
-81.52
|
0.12
|
-3.75
|
-15.92
|
| Operating Income Ratio |
0
|
0
|
0
|
-254.41
|
-244.58
|
-230.44
|
-85.37
|
0.21
|
-1.98
|
-81.32
|
| Total Other Income/Expenses Net |
$5.65 M
|
$3.85 M
|
$739.00 K
|
-$481.00 K
|
-$354.00 K
|
-$286.00 K
|
$7.00 K
|
$37.19 K
|
$179.24 K
|
$0.00
|
| Income Before Tax |
-$45.55 M
|
-$37.92 M
|
-$21.75 M
|
-$19.56 M
|
-$18.21 M
|
-$13.88 M
|
-$8.27 M
|
$3.73 M
|
-$8.55 M
|
-$3.35 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-260.83
|
-249.42
|
-235.29
|
-85.3
|
0.21
|
-1.94
|
-17.09
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$926.82 K
|
-$4.21 M
|
-$10.35 M
|
| Net Income |
-$45.55 M
|
-$37.92 M
|
-$21.75 M
|
-$19.56 M
|
-$18.21 M
|
-$13.88 M
|
-$8.27 M
|
$3.73 M
|
-$12.33 M
|
-$5.60 M
|
| Net Income Ratio |
0
|
0
|
0
|
-260.83
|
-249.42
|
-235.29
|
-85.3
|
0.21
|
-2.8
|
-28.6
|
| EPS |
-0.98 |
-1.05 |
-2.68 |
-14.12 |
-19.31 |
-27.27 |
-69.09 |
28.45 |
-103.6 |
-63.55 |
| EPS Diluted |
-0.98 |
-1.05 |
-2.68 |
-14.12 |
-19.31 |
-27.27 |
-8.1 |
28.45 |
-103.6 |
-63.55 |
| Weighted Average Shares Out |
$46.56 M
|
$36.21 M
|
$10.26 M
|
$1.39 M
|
$1.92 M
|
$1.01 M
|
$240.28 K
|
$201.59 K
|
$165.06 K
|
$137.59 K
|
| Weighted Average Shares Out Diluted |
$46.56 M
|
$36.21 M
|
$10.28 M
|
$1.39 M
|
$1.92 M
|
$1.01 M
|
$240.28 K
|
$201.59 K
|
$165.06 K
|
$137.60 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
